PeerView Institute for Medical Education at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
PeerView Institute for Medical Education brings 3 presentations to ASH 2026 in New Orleans. Its program centres on continuing education for hematologists, mainly CAR-T therapy, bispecific antibodies and BTK inhibitors. It supports symposia on lymphoma, myeloma, CLL and mantle cell lymphoma.
| Organization | ASH 2026 Attendance |
|---|---|
PeerView Institute for Medical Education New York, NY | |
Accredited continuing medical education provider producing live and online programs for clinicians, including hematology and oncology symposia. | Symposium Fri Dec 11 7:00am–10:00am Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity. Symposium Fri Dec 11 11:00am–2:00pm Advancing Bispecific Pathways in ALL: How Clinical Experience and New Science are Informing Off-the-Shelf Innovation Bispecific T-cell engagers in B-cell acute lymphoblastic leukemia, including gentler next-generation versions for patients unsuited to or relapsing after CAR-T. Symposium Fri Dec 11 11:00am–2:00pm Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse. Symposium Fri Dec 11 3:00pm–6:00pm FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment Time-limited frontline chronic lymphocytic leukemia treatment pairing Bruton tyrosine kinase and Bcl-2 inhibitors, tailored to patient goals and risk. Symposium Fri Dec 11 3:00pm–6:00pm The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-Line to Frontline Care Bispecific antibodies moving from late to early treatment of non-Hodgkin lymphoma, with outpatient step-up dosing and control of immune side effects. Symposium Fri Dec 11 7:00pm–10:00pm Accelerating CARs for Lymphoma: Expert Workshops on CAR-T Standards, Sequencing, and Emerging Cellular Therapy Platforms CAR-T as standard lymphoma care and what comes next, including dual-target, faster-manufactured, and in vivo versions that could widen patient access. Poster Sat Dec 12 5:30pm–7:30pm Poster Sun Dec 13 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm |
Find decision makers at PeerView Institute for Medical Education
Tell us what you sell and we’ll find the people at PeerView Institute for Medical Education most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction